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Video-assisted thoracic surgery (VATS)
A B S T R A C T
Background and purpose: An optimal pulmonary localization technique for video-assisted thoracic surgery
(VATS) of small lung nodules has not yet been established. The LOcalization of Ground-glass-opacity and pul-
monary lesions for mInimal Surgery (LOGIS) registry aims to establish a multicenter database and investigate the
usefulness and safety of localization techniques for small pulmonary lesions in individuals undergoing VATS.
Methods/Design: The LOGIS registry is a large-scale, multicenter cohort study, aiming to enroll 825 patients at 10
institutions. Based on the inclusion and exclusion criteria, all study participants with pulmonary lesions in-
dicated for VATS will be screened and enrolled at each site. All study participants will undergo preoperative
lesion localization by the hook-wire or lipiodol localization methods according to site-speciﬁc methods. Within a
few hours of marking, thoracoscopic surgery will be done under general anesthesia by experienced thoracoscopic
surgeons. The primary endpoints are the success and complication rates of the two localization techniques.
Secondary endpoints include procedure duration, recurrence rate, and all-cause mortality. Study participant
enrollment will be completed within 2 years. Procedure success rates and incidence of complications will be
analyzed based on computed tomography ﬁndings. Procedure duration, recurrence rate, and all-cause mortality
will be compared between the two techniques. The study will require 5 years for completion, including 6 months
of preparation, 3.5 years for recruitment, and 1 year of follow-up endpoint assessment.
Discussion: The LOGIS registry, once complete, will provide objective comparative results regarding the use-
fulness and safety of the lipiodol and hook-wire localization techniques.
1. Introduction
The diagnosis rate of small pulmonary lung nodules has been in-
creasing with the increasing use of computed tomography (CT) in lung
cancer screening and daily practice [1–3]. While malignancy rates of
small pulmonary lesions depend on nodule size and characteristics, they
are not negligible upon with subsolid nodules as well as solid nodules
[4,5]. Therefore, proper management of small pulmonary nodules is an
important issue [6]. Because of its safety and minimal invasiveness,
video-assisted thoracoscopic surgery (VATS) is widely used for diag-
nosis and treatment of small pulmonary nodules [7]. However, if the
targeted pulmonary lesion is too small or too deeply located to be
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visible or palpable, pre-VATS localization is mandatory for successful
minimally invasive surgery without open thoracotomy conversion
[8–10].
Pulmonary localization techniques for small lung nodules vary
greatly and employ various materials or methods [11–14]. However, an
optimal pulmonary lesion localization method that is eﬀective and safe
for VATS has not yet been established. Currently, CT-guided hook-wire
localization is the most widely used method for pre-VATS localization
[15]. However, a previous meta-analysis reported that CT-guided hook-
wire localization exhibited a lower success rate and higher complica-
tion rate than microcoil and lipiodol localization [16]. Lipiodol locali-
zation for small lung nodules prior to VATS has been reported to be
accurate and safe, with high success rates and low complication rates
[13,17,18]. Pulmonary lesion localization using lipiodol has been
consistently reported as exhibiting a success rate of over 90% [16]. The
ongoing LOcalization of Ground-glass-opacity for mInimal Surgery
(LOGIS) trial involves comparison of eﬀectiveness and post-procedural
complications between the hook-wire and lipiodol localization methods
for VATS resection of ground-glass opacity (GGO) lesions [15]. How-
ever, depending on nodule characteristics and operator experience,
there could be variations in results. Therefore, it is necessary that multi-
institutional cohorts of a larger scale be established to comparatively
evaluate the safety and eﬀectiveness of various pulmonary lesion lo-
calization techniques.
2. Materials and methods
2.1. Overall study design
The LOcalization of Ground-glass-opacity and pulmonary lesions for
mInimal Surgery (LOGIS) registry is a retrospective and prospective
multicenter registry of patients who have undergone or will undergo
pulmonary lesion localization by the hook-wire or lipiodol method
prior to pulmonary VATS (Fig. 1).
2.2. Study objectives
This study aims to establish a multicenter registry of pulmonary-
lesion localization techniques and investigate the usefulness and safety
of two diﬀerent localization methods for small pulmonary lesions in
individuals undergoing VATS.
2.3. Ethical considerations
The institutional review board of each participating institution re-
viewed and approved the study protocol. Informed patient consent will
be obtained for the prospective cohort, and its requirement will be
waived for the retrospective cohort. Patient records and data will be
anonymized and de-identiﬁed prior to analysis.
2.4. Funding
The LOGIS registry is a physician-initiated registry, sponsored by
Guerbet. Therefore, the authors are solely responsible for the design
and conduct of this study, analysis of all study data, and drafting and
editing of the manuscript, as well as its ﬁnal contents.
2.5. Targeted population
Based on the inclusion and exclusion criteria, all subjects with
pulmonary lesions indicated for VATS, including solid and GGO no-
dules, will be screened and enrolled at each site.
The inclusion criteria are as follows: consenting adults who is equal
or older than 19 years of age; pulmonary lesions (solid nodules or GGO
nodules) indicated for VATS; no contraindications for surgery; and
willingness to sign the informed consent form.
The exclusion criteria are: contraindication for surgery; un-
cooperative behavior; severe neurologic or physiologic problems; un-
willingness or inability to provide informed consent; and pregnancy.
2.6. Study endpoints
The primary endpoints of the LOGIS registry are the procedure
success rates and complication rates of the lipiodol and hook-wire lo-
calization methods. Secondary endpoints include procedure duration,
recurrence rate, and all-cause mortality. Procedure duration is deﬁned
as the period from the start of pre-localization CT to the end of pul-
monary-lesion localization. The end of localization is deﬁned as the
time at which the needle leaves the lungs after lipiodol administration
or the time at which the hook-wire is anchored onto the lesion.
Recurrence is deﬁned by the discovery and diagnosis of new lesions
through histological examination or medical imaging during the follow-
up period. All-cause mortality includes death from any reason.
2.7. Participating sites and eligibility criteria for participation
The requirements for participating sites to contribute to the LOGIS
registry are same as those stipulated for the LOGIS trial [15].
Minimum requirements for participating sites include:
(1) Experienced radiologists who have at least 1 year of experience
with at least 30 cases of lipiodol or hook-wire localization for
pulmonary nodules
(2) Experienced thoracic surgeon who has at least 3 years of experience
with at least 100 cases of VATS
(3) Multi-detector CT scanner (≥16-slice) for localization
Overall ten university hospitals are participating in this multicenter
registry. The lipiodol-guided localization group is consisted of ﬁve
hospitals and the hook-wire-guided localization group is composed of
the remaining ﬁve hospitals, based on their routine localization prac-
tices at each site.
2.8. Patient recruitment and evaluation
The LOGIS registry includes patients who have undergone or will
undergo VATS for lung lesions after localization by the lipiodol or hook-
wire methods. Following surgery, patient demographic characteristics,Fig. 1. Overall study design of the LOGIS registry.
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targeted medical history, and CT ﬁndings will be recorded using online
electronic case report forms (eCRFs). Eligible patients treated between
January 1, 2011, and December 31, 2016, will be retrospectively re-
viewed and enrolled in a retrospective cohort. From 2017, eligible
participants will be screened and enrolled prospectively in a pro-
spective cohort. All prospectively enrolled subjects will be required to
sign consent forms voluntarily; only those patients whose consent forms
have been received by the institution will be allowed to participate in
the clinical study. Before gathering informed consent, the participants
will be explained the study details, including (1) study purpose; (2)
autonomy of participation; (3) compensation for participation; (4) po-
tential danger and beneﬁts; and (5) ways to contact the researchers.
Each enrolled patient is designated a baseline number (patient study
ID), which is recorded in the corresponding case report form and re-
tained until the end of the clinical study. Clinical trial institutions will
monitor each patient through master ﬁles.
2.9. CT-guided lung localization and thoracoscopic surgery
All subjects will undergo preoperative lung localization at their
respective sites according to site-speciﬁc methods. They will be trans-
ferred to the operating room immediately after localization. Within a
few hours of marking, thoracoscopic surgery will be performed under
general anesthesia. Patients with primary lung cancer will further re-
ceive thoracoscopic lobectomy or segmentectomy with lymph-node
dissection.
2.10. eCRF and data management
After surgery, participants will be assessed every 3–6 months for a
year. Each participating site will provide the data of enrolled patients,
including eligibility criteria, baseline characteristics, pre-localization
and localization CT characteristics, surgical characteristics, pathologic
ﬁndings, and follow-up outcomes, through eCRFs. Baseline character-
istics will include sex, age, height, weight, body mass index, and pre-
vious/current medical ﬁndings (hypertension, diabetes, cancer, sur-
gery, heart diseases, lung diseases, alcohol, smoking, allergy, and
medication). Pre-localization CT data will include imaging protocol
(equipment, contrast material, tube voltage, reconstruction method,
and radiation dose) and ﬁndings (number, size, location, type, and
multiplicity of lesions, lymph node metastasis, pleural eﬀusion, and
metastasis). Localization CT data will include imaging protocol
(equipment, radiation dose, and method), lesion characteristics (lesion
size, location, and type), operator experience, and procedural char-
acteristics (position, puncture time, pleura-to-nodule distance, start
time, outcome, and complications).
Pathologic ﬁndings will include diagnosis (granuloma, atypical
adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive
and invasive adenocarcinomas, metastasis, and others), gene mutation
ﬁndings, and cancer stage. Follow-up outcome data will record recur-
rence and death. Each LOGIS investigator will get an ID and a password
for accessing the eCRFs. After the eCRFs are entered by the partici-
pating sites, a dedicated biostatistician at the data coordinating center
will check the data for possible errors, after which, the eCRF will be
locked until data analysis. Severance hospital will serve as the data
coordinating center for this study.
2.11. Statistical methods
2.11.1. Sample size and power calculation
The primary endpoint of the LOGIS registry is comparison of success
rates between CT-guided lipiodol and hook-wire localization for lung-
nodule VATS. In a previous meta-analysis [16], the mean success rates
of lipiodol and hook-wire localization for pulmonary nodules were
found to be 99% and 94%, respectively. Based on previous results, we
performed sample size calculation by two independent proportions
power analysis, with a signiﬁcance level of 0.05 and 90% statistical
power. In a 1:2 ratio, we will enroll 220 and 440 patients, respectively,
in the lipiodol and hook-wire localization groups. Assuming a 20%
drop-out rate, we will enroll a total of 825 subjects. Sample size cal-
culation was performed with the PASS software (ver. 12, power analysis
and sample-size package, NCSS statistical software).
2.11.2. Primary statistical analysis
Categorical baseline characteristics will be expressed as number and
percentage, and continuous variables will be expressed as mean and
standard deviation. For the primary endpoints, procedure success rates
and incidence of post-procedural complications, both evaluated based
on CT ﬁndings will be analyzed by Student's t-test or chi-square test. If
the results of this study demonstrate substantial variation among the
participating sites, linear mixed model or generalized linear mixed
model analysis will be performed to account for the clustering eﬀect
according to site. For the secondary endpoints, the procedure duration
will be analyzed by Student's t-test. Cumulative survival rate or recur-
rence rate will be presented by a Kaplan–Meier curve and compared by
an intergroup log-rank test. Hazard ratios for all-cause mortality, along
with 95% conﬁdence intervals, will be calculated by Cox proportional
hazard regression or competing risk analysis. P-values< 0.05 will be
considered statistically signiﬁcant. All statistical analyses will be per-
formed with the SPSS software (version 23.0; Statistical Package for the
Social Sciences, Chicago, IL, USA).
3. Discussion
The LOGIS registry is a multicenter cohort study for comparison of
success and complication rates between hook-wire and lipiodol locali-
zation for VATS for small pulmonary lesions, including GGO and solid
nodules.
Owing to recent technological advances in CT as well as the in-
creasing number of lung cancer screening tests, the rate of diagnosis of
small lung nodules has been increasing [5,19]. Nevertheless, it is still
challenging to diﬀerentiate between benign and malignant lesions
based solely on CT ﬁndings [20,21]. Solid nodules and persistent GGO
lesions pose a risk of cancer [5,13]. However, percutaneous lung biopsy
has been known to lack diagnostic accuracy for small nodules and GGO
lesions [22].
With recent advances in surgical techniques, the use of VATS for
diagnosis and treatment of small nodules has been increasing because of
its safety and minimal invasiveness [7,23]. However, conversion to
thoracotomy because of VATS failure is not rare [9,11]. It is because
small pulmonary nodules and GGO lesions are not easily recognizable
by palpation or inspection. Therefore, accurate and safe localization
method for lung lesions prior to VATS is necessary [24].
There are various preoperative localization methods for identifying
small lung lesions to reduce the thoracotomy conversion rate of VATS.
These localization techniques involve ultrasonography, hook wire, mi-
crocoil, methylene blue, indocyanine green, radionuclides, lipiodol,
barium, and iodine contrast agents [11–14,24,25]. Although CT-guided
hook-wire localization is the most widely used localization technique
and is considered both safe and eﬀective for VATS, the risk of dis-
lodgement or migration of the hook-wire after localization is a major
limitation of this technique and has resulted in wide variation of its
reported success rates [16]. In contrast, lipiodol localization has been
reported as constantly exhibiting success rates of over 90% [16]. Sev-
eral studies have reported on the simplicity and usefulness of pre-
operative lipiodol localization for identiﬁcation of small or deeply lo-
cated pulmonary nodules for thoracoscopic surgery [13,14,26].
Lipiodol localization has the advantages of being stable and easy to
handle; additionally, it does not induce inﬂammatory responses, which
can aﬀect the pathologic ﬁndings of lesions [27,28]. Moreover, there
has been no report of air embolism after lipiodol localization [16].
However, post-lipiodol localization surgery requires ﬂuoroscopy, which
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is a major drawback of this technique [13]. Despite the availability of
various localization methods, the optimal method for preoperative lo-
calization of pulmonary nodules has not been established, which has
limited the success rate of VATS for small lung lesions [24]. Further-
more, hook-wire localization, the most widely used pre-VATS locali-
zation method, suﬀers from inconsistent success rates relative to other
localization methods [16].
The ongoing LOGIS trial is a prospective multicenter, controlled,
comparative phase III trial designed to demonstrate the comparative
usefulness and safety of lipiodol and hook-wire localization for GGO
lung lesions [15]. Although the LOGIS trial is expected to provide va-
luable information, its non-randomized controlled study design renders
it prone to selection and assessment bias. Furthermore, the small
sample size (125 subjects per group) might nullify attempts to over-
come any diﬀerences in experience, skill, and preference among radi-
ologists and surgeons. To overcome these limitations, we intend to es-
tablish the LOGIS registry, a larger scale of multicenter registry, to
compare the success rates and complication rates of localization tech-
niques in individuals undergoing VATS for small pulmonary lesions.
The LOGIS registry has several advantages over the LOGIS trial. First,
the LOGIS registry is a large-scale, multicenter cohort study, aiming to
enroll over 800 patients. For this reason, the LOGIS registry has broader
inclusion criteria than the LOGIS trial, which will enable us to enroll
patients with solid or GGO nodules. Second, the number of partici-
pating sites has been increased from 8 institutions in the LOGIS trial to
10 institutions in this registry. Third, detailed information regarding
patient characteristics, procedures, surgical characteristics, and out-
comes will be collected using the convenient eCRF system, which will
ensure eﬃcient and prompt data collection.
The LOGIS registry is the ﬁrst large-scale cohort study for compar-
ison of pulmonary lesion localization methods. Upon completion, the
LOGIS registry will provide objective comparative results regarding the
usefulness and safety of the lipiodol and hook-wire localization tech-
niques.
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